Wockhardt gets US nod for Levofloxacin
New Delhi: Pharmaceutical major Wockhardt has received tentative approval from the US Food and Drug Administration (FDA) for marketing the 250 mg, 500 mg and 750 mg tablets of Levofloxacin, used for treatment of bacterial infections.
Levofloxacin is the generic name for the brand Levaquin, marketed in the US by Ortho Mcneil (Johnson & Johnson). Wockhardt will launch the product immediately upon expiration of the patent on June 20, 2011, the company said in a statement.
Levofloxacin is a very widely used antibacterial drug and belongs to the fluoroquinolone group. The total market for Levofloxacin tablets in the US is about $1.6 billion.
“Ability to launch products on the date of patent expiration is the most critical element of success in the highly competitive US generics market,” said Wockhardt chairman Habil Khorakiwala.
“Receiving the tentative approval will enable Wockhardt to plan a successful launch of Levofloxacin in the US. We have had a good start to the year 2010, with two tentative approvals in as many weeks,” he added.
The Levofloxacin tablets will be manufactured at the US FDA certified formulation plant at Waluj, Aurangabad, the company said.
More from India
More from World
More from Sports
More from Entertaiment
- Watch - Huge fire breaks out at petrol pump in Kota, Rajasthan
- NSG now 'nine times' stronger; receives technological strength from 12 countries!
- Bihar: Congress leader Brajesh Pandey accused of running sex racket
- Panel discussion over why SP government is backing Gayatri Prajapati
- BJP MP Yogi Adityanath compares Akhilesh Yadav with 'Aurangzeb' and 'Kans'
- Reliance Jio's tariff plan from April 1; voice calls, roaming to be free: Mukesh Ambani
- 7th Pay Commission: Allowances committee raises HRA to 30%?
- Virat Kohli thanks sprint legend Usain Bolt for congratulating him on 'record' Puma deal
- IPL 2017 Auction: Reaction-filled Twitter erupts with emotions!
- Virat Kohli becomes first Indian sportsperson to sign Rs 100-crore endorsement deal